menu search

BDTX / Why Is Black Diamond Therapeutics (BDTX) Stock Up 82%?

Why Is Black Diamond Therapeutics (BDTX) Stock Up 82%?
Black Diamond Therapeutics (NASDAQ: BDTX ) stock is seeing massive gains on Tuesday after releasing data from the dose escalation portion of the Phase 1 clinical study. That clinical trial covers the use of BDTX-1535 as a treatment for non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM). Read More
Posted: Jun 27 2023, 11:00
Author Name: InvestorPlace
Views: 112594

BDTX News  

Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

By GlobeNewsWire
October 4, 2023

Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology more_horizontal

Why Shares of Black Diamond Therapeutics Skyrocketed This Week

By The Motley Fool
June 29, 2023

Why Shares of Black Diamond Therapeutics Skyrocketed This Week

Lung cancer is the deadliest form of cancer in the U.S. Black Diamond Therapeutics' NSCLC therapy is in early trials. The pharmaceutical company used more_horizontal

Black Diamond Therapeutics stock rockets after positive trial data shows anti-tumor activity

By Proactive Investors
June 27, 2023

Black Diamond Therapeutics stock rockets after positive trial data shows anti-tumor activity

Black Diamond Therapeutics Inc shares doubled after it saw positive initial dose escalation data from a study demonstrating the anti-tumor activity of more_horizontal

Why Is Black Diamond Therapeutics (BDTX) Stock Up 82%?

By InvestorPlace
June 27, 2023

Why Is Black Diamond Therapeutics (BDTX) Stock Up 82%?

Black Diamond Therapeutics (NASDAQ: BDTX ) stock is seeing massive gains on Tuesday after releasing data from the dose escalation portion of the Phase more_horizontal

Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference

By GlobeNewsWire
June 2, 2023

Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference

CAMBRIDGE, Mass. and NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology more_horizontal

Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

By GlobeNewsWire
February 27, 2023

Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

CAMBRIDGE, Mass. and NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology more_horizontal

Down 32.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX)

By Zacks Investment Research
December 9, 2022

Down 32.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX)

Black Diamond (BDTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement am more_horizontal


Search within

Pages Search Results: